Trevena, Inc. (TRVN) News
Filter TRVN News Items
TRVN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TRVN News Highlights
- TRVN's 30 day story count now stands at 2.
- Over the past 1 day, the trend for TRVN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about TRVN are CNS, DEC and PRE.
Latest TRVN News From Around the Web
Below are the latest news stories about TREVENA INC that investors may wish to consider to help them evaluate TRVN as an investment opportunity.
Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant ExerciseCHESTERBROOK, Pa., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has closed its previously announced offering for the issuance and sale of 2,779,906 shares of common stock (or pre-funded warrants in lieu thereof) of Trevena and warrants to purchase up to an aggregate of 2,77 |
Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant ExerciseCHESTERBROOK, Pa., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has entered into definitive agreements for the issuance and sale of 2,779,906 shares of common stock (or pre-funded warrants in lieu thereof) of Trevena and warrants to purchase up to an aggregate of 2,779,906 s |
Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting-- Presentation highlighted promising results of TRV045 in nonclinical models of neuropathic pain including mechanical and cold-stimulus evoked nociceptive pain in a dose-related manner TRV045 selectively targets the S1P1 receptor without associated lymphopenia -- CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders |
Trevena Awarded OLINVYK Agreement with Premier, Inc.CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, has been awarded a national group purchasing agreement for OLINVYK with Premier, Inc. Effective December 1, 2023, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for OLINVYK. P |
Trevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn InjuriesResults from investigator-initiated RELIEVE study will be presented at the 2024 American Burn Association (ABA) Annual Meeting in Chicago from April 9th-12thCHESTERBROOK, Pa., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, announced today the acceptance of an abstract based on the pRospective, case-controlled Evaluation of oLIc |
Trevena Third Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsTrevena ( NASDAQ:TRVN ) Third Quarter 2023 Results Key Financial Results Net loss: US$7.93m (loss narrowed by 48% from... |
Trevena, Inc. (NASDAQ:TRVN) Q3 2023 Earnings Call TranscriptTrevena, Inc. (NASDAQ:TRVN) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Greetings and welcome to Trevena, Inc. Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It is now […] |
Trevena Reports Third Quarter 2023 Results and Provides Business UpdateCompany previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement Company reported favorable safety and tolerability data from TRV045 POC studies Three abstracts for OLINVYK presented at American Society of Anesthesiologists (ASA) Conference $15 million tranche from ex-US royalty-based financing agreement received in September Company to host conference call today, November 14, 2023 at 8:00 a |
Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023Company to host a Conference Call & Webcast at 8:00 a.m. ETCHESTERBROOK, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the third quarter ended September 30, 2023, prior to the market open on Tuesday, November 14, 2023. The Company will host a conference call a |
Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept StudiesTRV045 was well tolerated with results generally consistent with prior first-in-human study No drug-related adverse events and no serious adverse events reported No drug-related lymphopenia, bradycardia, or change in blood pressure reported CHESTERBROOK, Pa., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported topline |